A diabetes injection appears more effective at promoting weight loss than one of the leading obesity drugs, according to tests results.
Patients receiving liraglutide, which contains a satiety hormone, were twice as likely to lose significant amounts of weight as those on orlistat.
Not only does the drug appear to curb hunger, it also reduces type 2 diabetes risk factors, the Lancet study found.
The study author is a paid consultant of the company which produces the drug.
There are limitations: the drug must be injected every day as it would otherwise be broken down in the gut, and it is expensive - £500 for six months of treatment.
Further studies are needed to establish the longer term risk-benefit ratio as this trial on 564 patients ran for just 20 weeks.
Over this period, three groups of patients in 19 hospitals were put on a diet reduced by 500 calories a day and asked to exercise.
One set received a placebo, the second orlistat - available by prescription as Xenical - and a third liraglutide, also known as Victoza.
Over the 20 weeks, more than three quarters of those on 3mg of liraglutide lost more than 5% weight, compared with 44% with 120mg of orlistat and 30% with a placebo.
This on average translated as more than a stone in weight.
BBC News has contributed to the report.
The behavior of the Russian inspector satellite, which was launched in the autumn of 2017, puzzles military officials in the United States
Ukrainian bloggers draw a parallel between the events in East Timor and the Crimea. Any comparison has a right to exist, but a detailed analysis of the situation does not give a promising forecast to Ukraine
Vladimir Putin is planning to attend the wedding ceremony of Austria's Foreign Minister Karin Kneissl on the way to Berlin